Two mechanisms of synergism when amphotericin B is used in combination with actinomycin D or 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea against the human promyelocytic leukemia cell line HL-60.
The toxic effects of the combinations of amphotericin B (AmB) and actinomycin D or AmB and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea were measured against the human promyelocytic leukemia cells HL-60. The toxicities of both drug combinations were greater than the additive toxicity of each of the drugs used singly, but the exact conditions under which synergism was achieved differed for each combination. The synergism achieved by the AmB-actinomycin combination was accompanied by an AmB-induced increase in uptake of actinomycin D by the HL-60 cells, whereas the synergism of the AmB-1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea combination could be linked to potentiation by 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea of AmB-induced oxidative injury. These results indicate that the synergism of these two drug combinations was caused by different mechanisms.
Vertut-Croquin
A
A
Brajtburg
J
J
Medoff
G
G
D000666:Amphotericin B / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002452:Cell Count; D002460:Cell Line; D003609:Dactinomycin / Q000378:metabolism / Q000494:pharmacology*; D004357:Drug Synergism; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000032:analysis; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism / Q000473:pathology*; D008130:Lomustine / Q000378:metabolism / Q000494:pharmacology*; D008315:Malondialdehyde / Q000378:metabolism; D010084:Oxidation-Reduction; D011188:Potassium / Q000032:analysis; D013936:Thymidine / Q000378:metabolism
D003609:Dactinomycin; D008315:Malondialdehyde; D008130:Lomustine; D000666:Amphotericin B; D007770:L-Lactate Dehydrogenase; D011188:Potassium; D013936:Thymidine